Company Information

Market
HKEX Main Board
Listing Date
2021-06-30
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG4672N1198
Southbound Connect
Shanghai · Shenzhen

Related Securities

Industry

Innovative Drugs & Biologics 2.03%
124 stocks in this industry
Down 91 Up 17
Industry RankingsValue (HKD)Rank
Revenue (Last FY)25.81B8/112
Net Profit (Last FY)25.20B1/125
ROE (Last FY)36.91%4/117

Change is the 2026-11-13 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
苏慰国 Executive Director
郑泽锋 Executive Director
施熙德 Non-Executive Director
杨凌 Non-Executive Director
Dr Renu BHATIA(言思雅医生) Independent Non-Executive Director
Dr Chaohong HU Independent Non-Executive Director
陈邵文 Independent Non-Executive Director
黄德伟 Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-05-13.

About this page

This page shows HUTCHMED (00013) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect